{'fraction_non_alphanumeric': 0.04448742746615087, 'fraction_numerical': 0.027079303675048357, 'mean_word_length': 5.641025641025641, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Safety and efficacy of faldaprevir with pegylated interferon alfa‐2a and ribavirin in Japanese patients with chronic genotype‐1 hepatitis C infection

Faldaprevir (BI 201335) is a potent once‐daily (QD) NS3/4A protease inhibitor for the treatment of patients with genotype‐1 (GT‐1) hepatitis C virus (HCV). The aim of this study was to evaluate the safety, pharmacokinetics and efficacy of faldaprevir plus pegylated interferon alfa‐2a (PegIFN) and ribavirin (RBV) in Japanese patients infected with chronic GT‐1 HCV.